# Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

> **NCT04011410** · PHASE2 · COMPLETED · sponsor: **Patrick Hensley** · enrollment: 20 (actual)

## Conditions studied

- Prostate Cancer Recurrent

## Interventions

- **DRUG:** Hydroxychloroquine Sulfate 200Mg Tab

## Key facts

- **NCT ID:** NCT04011410
- **Lead sponsor:** Patrick Hensley
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-03
- **Primary completion:** 2024-03-08
- **Final completion:** 2024-03-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04011410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04011410, "Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04011410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*